JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) just unveiled an announcement.
JOINN Laboratories has observed unusual price movements in its shares, which may be influenced by a new FDA scheme to eliminate animal testing for monoclonal antibodies and other drugs. The company views this as an opportunity to align with industry trends towards alternative research methods, such as in vitro testing, which supports its long-term development goals and commitment to sustainable pharmaceutical research.
More about JOINN Laboratories (China) Co., Ltd. Class H
JOINN Laboratories (China) Co., Ltd. is a company based in the People’s Republic of China that specializes in non-clinical drug research. The company is committed to providing high-quality technical services and adheres to the ‘3R’ principle of animal experiments, focusing on Reduction, Refinement, and Replacement. It has been actively developing organoid research to replace live animal testing.
YTD Price Performance: 26.20%
Average Trading Volume: 3,209,453
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.62B
For a thorough assessment of 6127 stock, go to TipRanks’ Stock Analysis page.